Press release
Exosomes Pipeline, FDA Approvals, Clinical Trials Developments, and Companies | Capricor Therapeutics, Direct Biologics, Regeneus, OBCTCD24, AVEM HealthCare, Cellular Biomedicine Group and others
Exosomes Pipeline
Key Takeaways from the Exosomes Pipeline Report
• DelveInsight's Exosomes pipeline report depicts a robust space with 60+ active players working to develop 110+ pipeline therapies for Exosomes treatment.
• The leading companies working in the Exosomes Market include Capricor Therapeutics, Direct Biologics, Regeneus, OBCTCD24, AVEM HealthCare, Cellular Biomedicine Group, Aegle Therapeutics, Organicell Regenerative Medicine, Codiak BioSciences, Cellular Biomedicine Group, StemXO Therapeutics, Cells for Cells, RION, Cell Care Therapeutics, Novadip, Ilias, ReNeuron, Evora Bioscineces, Coya Therapeutics, ShiftBio Inc., Exostemtech, Celularity, Azymus Therapeutics, and others.
• Promising Exosomes Pipeline Therapies in the various stages of development include Exosome ointment, EV-Pure™, Zofin, Olmutinib, and others.
• December 2023: Direct Biologics LLC announced a study of Phase 3 clinical trials for ExoFlo. To evaluate the safety and efficacy of intravenous (IV) administration of bone marrow mesenchymal stem cell derived extracellular vesicles (EVs), ExoFlo, versus placebo for the treatment of hospitalized patients with moderate-to-severe Acute Respiratory Distress Syndrome (ARDS).
• November 2023: Organicell Regenerative Medicine announced a study of Phase 1 & 2 clinical trials for Zofin. The purpose of this research study is to evaluate the safety and potential efficacy of Intravenous Infusion of Zofin for treatment of moderate to severe Acute Respiratory Syndrome (SARS) related to COVID-19 infection vs Placebo.
• October 2023: Vitti Labs LLC announced a study of Phase 1 clinical trials for EV-Pure™. The VL-POI-01 study is designed to evaluate the safety and efficacy of human placental mesenchymal stem cell derived exosome treatment in patients with premature ovarian insufficiency (POI) and diminished ovarian reserve.
Request a sample and discover the recent advances in Exosomes Treatment Drugs @ Exosomes Pipeline Outlook Report- https://www.delveinsight.com/report-store/exosomes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
In the Exosomes pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Exosomes collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Exosomes Overview
An exosome is a type of extracellular vesicle (EV), a family of nanometer-scale, biomolecule-filled, lipid-wrapped packages released by most cells. Exosomes are released from cells upon fusion of an intermediate endocytic compartment, the multivesicular body (MVB), with the plasma membrane. This liberates intraluminal vesicles (ILVs) into the extracellular milieu and the vesicles thereby released are what we know as exosomes.
Find out more about Exosomes Treatment Landscape @ Drugs for Exosomes Treatment- https://www.delveinsight.com/sample-request/exosomes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Exosomes Emerging Drugs Profile
• CAP-1002: Capricor
• Progenza: Regeneus
• AGLE 102: Aegle Therapeutics
• Zofin: Organicell Regenerative Medicine
• Exo-101: Exogenus Therapeutics
• COYA 201: Coya Therapeutics
Exosomes Pipeline Therapeutics Assessment
There are approx. 60+ key companies which are developing the therapies for Exosomes. The Exosomes Companies which have their Exosomes drug candidates in the most advanced stage, i.e. phase III include, Capricor.
DelveInsight's Exosomes pipeline report covers around 110+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Exosomes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
Exosomes Products have been categorized under various Molecule types such as
• Oligonucleotide
• Peptide
• Small molecule
Learn more about the emerging Exosomes Pipeline Therapies @ Exosomes Clinical Trials Assessment- https://www.delveinsight.com/sample-request/exosomes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Exosomes Pipeline Report
• Coverage- Global
• Exosomes Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Exosomes Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Exosomes Companies- Capricor Therapeutics, Direct Biologics, Regeneus, OBCTCD24, AVEM HealthCare, Cellular Biomedicine Group, Aegle Therapeutics, Organicell Regenerative Medicine, Codiak BioSciences, Cellular Biomedicine Group, StemXO Therapeutics, Cells for Cells, RION, Cell Care Therapeutics, Novadip, Ilias, ReNeuron, Evora Bioscineces, Coya Therapeutics, ShiftBio Inc., Exostemtech, Celularity, Azymus Therapeutics, and others.
• Exosomes Pipeline Therapies- Exosome ointment, EV-Pure™, Zofin, Olmutinib, and others.
Dive deep into rich insights for new drugs for Exosomes Treatment, Visit @ Exosomes Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/exosomes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Exosomes: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Exosomes- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. CAP-1002: Capricor
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Progenza: Regeneus
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. StemXO Endosome Therapy: Stem XO Therapeutics
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Exo-101: Exogenus Therapeutics
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Exosome - Collaborations Assessment- Licensing / Partnering / Funding
21. Exosomes- Unmet Needs
22. Exosomes- Market Drivers and Barriers
23. Appendix
For further information on the Exosomes pipeline therapeutics, reach out @ Exosomes Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/exosomes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
List of Important Published Links-
https://dbook.mn.co/posts/48401881
https://lxgonline.mn.co/posts/navigating-the-landscape-of-hypertriglyceridemia-market-current-trends-and-future-prospects
https://www.penname.me/@dennydones99
https://community.fyers.in/member/7Yldtdsvui
https://spurstartup.mn.co/posts/48406045
https://pressurecooker.mn.co/posts/48406225
https://regenerative-future.mn.co/posts/navigating-the-hypertriglyceridemia-market-innovations-and-challenges
https://commiss.io/dennydones
https://www.pledgeme.co.nz/profiles/221820/
https://brave-comfort.mn.co/posts/48409148
https://gamebook.mn.co/posts/navigating-the-landscape-of-the-hypertriglyceridemia-market
https://kktix.com/user/5068280
https://network-373.mn.co/posts/48353213
https://body-imagine.mn.co/posts/48353364
https://pimpmyairgun.mn.co/posts/48353478
https://gtribe.mn.co/posts/advancements-and-opportunities-in-the-vulvar-cancer-market
https://communenour.mn.co/posts/emerging-trends-and-market-dynamics-in-vulvar-cancer-treatment
https://synkretic.mn.co/posts/understanding-the-vulvar-cancer-market-trends-challenges-and-innovations
https://jlfa2020.mn.co/members/16644457
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/peripheral-nerve-repair-devices-market
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Exosomes Pipeline, FDA Approvals, Clinical Trials Developments, and Companies | Capricor Therapeutics, Direct Biologics, Regeneus, OBCTCD24, AVEM HealthCare, Cellular Biomedicine Group and others here
News-ID: 3347141 • Views: …
More Releases from DelveInsight Business Research LLP
Alpha-1 Protease Inhibitor Deficiency Market Size 2032: CSL Behring, Grifols The …
DelveInsight's "Alpha-1 Protease Inhibitor Deficiency Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Alpha-1 Protease Inhibitor Deficiency, historical and forecasted epidemiology as well as the Alpha-1 Protease Inhibitor Deficiency market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Key Takeaways from the Alpha-1 Protease Inhibitor Deficiency Market Research Report
• The increase in Alpha-1 Protease Inhibitor Deficiency Market Size…
Amyloidosis Market Size Report 2032: Attralus Inc., Novotech Pty Limited, Criter …
DelveInsight's "Amyloidosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Amyloidosis, historical and forecasted epidemiology as well as the Amyloidosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Key Takeaways from the Amyloidosis Market Research Report
• The increase in Amyloidosis Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies…
Basal Cell Nevus Syndrome Market Size Report 2032: Latest FDA Approvals, Emergin …
DelveInsight's "Basal Cell Nevus Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Basal Cell Nevus Syndrome, historical and forecasted epidemiology as well as the Basal Cell Nevus Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Key Takeaways from the Basal Cell Nevus Syndrome Market Research Report
• The increase in Basal Cell Nevus Syndrome Market Size…
Biliary Atresia Market Size Report 2032: Latest FDA Approvlas and Pipeline Repor …
DelveInsight's "Biliary Atresia Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Biliary Atresia, historical and forecasted epidemiology as well as the Biliary Atresia market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Key Takeaways from the Biliary Atresia Market Research Report
• The increase in Biliary Atresia Market Size is a direct consequence of the increasing…
More Releases for Exosome
Emerging Trends Exosome Diagnostics and Therapeutics Market Dominated by Evox Th …
An exosome diagnostic and therapeutic study approach represents the opportunity to expand and develop the liquid biopsy market, a growing sector in cancer diagnostics. Once they reach the recipient cells, cytoplasmic ingredients can alter their biology.
Access Sample Papers of Exosome Diagnostics and Therapeutics Market with 248 Pages and 6 Company Profiles Now at http://www.rnrmarketresearch.com/contacts/request-sample?rname=1529771 .
Growth in exosome diagnostic and therapeutic market in these regions attributes to the technological advancement in…
Exosome Diagnostic Market 2025 SWOT Analysis by Top Key Players-Aethlon Medical, …
Exosome Diagnostic Software market size estimations have been provided in terms of value (USD million). The Global Exosome Diagnostic Software industry report also identifies major market players and provides analysis in terms of company overview, financials, products & services, market trends, recent developments and growth strategies.
Get Sample Copy of this Report @ https://www.orianresearch.com/request-sample/566927
Exosome Diagnostic Market report offers a comprehensive insight into the development policies and plans in addition to manufacturing…
Exosome Diagnostic and Therapeutic Market is expected to reach $368 million by 2 …
Exosome Diagnostic and Therapeutic Market was valued at $39 million, and is expected to reach $368 million by 2022, supported by a CAGR of 37.8%.
Exosomes play a key role in facilitating cell-to-cell communication in the cancer prognosis. It suppresses the immune function by inducing apoptosis of activated cytotoxic T cells, which enable tumor progression in the human body. In addition, exosomes also stimulate the angiogenesis and migration leading to…
Exosome Diagnostic and Therapeutic Market – Qualitative Outlook On Growth 2025 …
Global Exosome Diagnostic and Therapeutic Market: Snapshot
The demand for diagnostic and therapeutic of exosome is projected to increment at a substantial CAGR during the forecast period of 2016 to 2024, gaining traction from a number of factors such as increasing prevalence of cancer, technological advancements in exosome isolation and pertaining analytical procedures, multiple awareness initiatives implemented by the government and healthcare organizations in various developed and emerging economies, and innovative…
Exosome Diagnostic and Therapeutic Market key players 2016 - 2024 : System Biosc …
Global Exosome Diagnostic and Therapeutic Market: Snapshot
The demand for diagnostic and therapeutic of exosome is projected to increment at a substantial CAGR during the forecast period of 2016 to 2024, gaining traction from a number of factors such as increasing prevalence of cancer, technological advancements in exosome isolation and pertaining analytical procedures, multiple awareness initiatives implemented by the government and healthcare organizations in various developed and emerging economies, and innovative…
Exosome Diagnostic and Therapeutics Market Size By 2027 | Thermo Fisher Scientif …
Future Market Insights in its recent research report titled “Exosome Diagnostic and Therapeutics Market: Global Industry Analysis (2012-2016) and Opportunity Assessment (2017-2027)” covers several factors that are influencing the robust growth of the global market. As per this research report, the global exosome diagnostic and therapeutic market is projected to expand at a high CAGR of 23.1% during the period of assessment. The exhaustive research publication includes key trends, opportunities,…
